Braz Nogueira J
Hospital Santa Maria, Faculdade de Medicina de Lisboa, Lisboa, Portugal.
Rev Port Cardiol. 2005 Jul-Aug;24(7-8):1007-13.
Left ventricular hypertrophy (LVH) is a well-known cardiovascular risk factor. Left ventricular mass reduction following anti-hypertensive treatment has also been demonstrated. However, few prospective and systematic clinical trials have analyzed whether regression of LVH is associated with improved prognosis. Two recently published LIFE substudies consistently show that the greater the reduction of LVH, assessed by ECG or by echocardiography in the setting of a prospective trial of anti-hypertensive treatment, the greater the reduction in cardiovascular event rates, independent of treatment modality and of decreases in blood pressure. These results support LVH regression as a therapeutic target in hypertension.
左心室肥厚（LVH）是一种众所周知的心血管危险因素。抗高血压治疗后左心室质量减轻也已得到证实。然而，很少有前瞻性和系统性的临床试验分析左心室肥厚的消退是否与预后改善相关。最近发表的两项LIFE子研究一致表明，在前瞻性抗高血压治疗试验中，通过心电图或超声心动图评估，左心室肥厚的消退程度越大，心血管事件发生率的降低幅度就越大，这与治疗方式和血压降低无关。这些结果支持将左心室肥厚的消退作为高血压的治疗靶点。
